Small Intestine News and Research

RSS

Risk factors for rare COVID-19 complications in children (MIS-C)

While the earlier waves of COVID-19 relatively spared children, some of the affected children have developed a systemic inflammatory condition, with occasionally fatal outcomes. Called multisystem inflammatory syndrome in children (MIS-C), its pathogenesis and risk factors are the subject of a new study on the medRxiv* preprint server.

21 May 2021

Owlstone Medical Launches Breath Testing for Digestive Health in Collaboration with Functional Gut Diagnostics and Functional Gut Clinic

Owlstone Medical today announced agreements with Functional Gut Clinic ("FGC") and Functional Gut Diagnostics (“FGD”).

From Owlstone Medical Ltd 18 May 2021

Is COVID-19 a new disease?

In a review recently published in The Lancet Respiratory Medicine journal by Osuchowski et al. (May 6th, 2021) the currently known pathophysiology of COVID-19 is laid out to describe the mechanistic features that make COVID-19 distinct from many conditions previously thought to be similar.

9 May 2021

Study describes IgG antibodies in Crohn's disease specific for human bacterial flagellins

Last year, Charles O. Elson, M.D., demonstrated a potential preventive treatment for Crohn's disease, a form of inflammatory bowel disease. He used a mouse model that included immune-reactive T cells from patients with Crohn's disease in a flagellin peptide-specific immunotherapy.

6 May 2021

SARS-CoV-2 study in human gut organoids

Most of the major life-threatening symptoms of COVID-19 disease are associated with the host's generation of an exacerbated pro-inflammatory immune response. Many studies have correlated the intensity of the immune response with the severity of disease.

3 May 2021

Some heart medications may facilitate SARS-CoV-2 infection through increasing ACE2 receptor levels

An interesting poster, just presented at the annual meeting of the American Society for Pharmacology and Experimental Therapeutics 2021, reports an association between the use of certain heart medications and the risk of COVID-19.

27 Apr 2021

Study may provide a basis for oral insulin development using DNP peptides

Researchers from Kumamoto University, Japan have found that DNP peptide, a small intestine-permeable cyclic peptide originally used as an insulin additive to improve absorption into the small intestinal, lowers blood glucose levels in mice.

26 Apr 2021

Probiotic L. acidophilus can effectively treat intestinal inflammation, research shows

Intestinal epithelial tight junctions (TJs) act as a functional and structural barrier against harmful antigens that promote intestinal inflammation in inflammatory bowel disease (IBD) and other inflammatory conditions of the gut.

20 Apr 2021

Study offers localized treatment direction for a cause of Crohn's disease

People with Crohn's disease are typically treated with powerful anti-inflammatory medications that act throughout their body, not just in their digestive tract, creating the potential for unintended, and often serious, side effects.

7 Apr 2021

A novel approach to oral vaccination against Covid-19

Scientists at the University of Würzburg together with a pharmaceutical company are working on a novel approach to oral vaccination against the coronavirus.

26 Mar 2021

Surgery is viable in more pancreatic cancer cases than commonly thought, study shows

Patients with stage II pancreatic cancer who are treated with chemotherapy followed by resection (an operation that removes the cancerous part of the organ, structure or tissue) live nearly twice as long as patients who receive only chemotherapy, according to a new Journal of the American College of Surgeons study published online in advance of print.

26 Mar 2021

PRRT technology may offer new treatment approaches for neuroendocrine tumors

Neuroendocrine tumors are cancers that begin in specialized cells called neuroendocrine cells. These cells have traits similar to those of nerve cells and hormone-producing cells.

9 Mar 2021

Mice study shows gut mycobiome influences the metabolism of processed diet

Studies of the microbiome in the human gut focus mainly on bacteria. Other microbes that are also present in the gut -- viruses, protists, archaea, and fungi -- have been largely overlooked.

8 Mar 2021

Nanotherapy shows potential for treating severe Crohn's disease

Scientists from the Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago demonstrated that a nanotherapy reduces intestinal inflammation and shrinks lesions in a rodent model of severe Crohn's disease.

17 Feb 2021

Researchers develop a better solution to treat short bowel syndrome

Short Bowel Syndrome (SBS) is a medical disorder caused by a lack of a fully functional small intestine.

17 Feb 2021

Regular walnut intake may help protect against negative outcomes associated with H. pylori infection

A new animal study, published in the Journal of Clinical Biochemistry and Nutrition, suggests regular walnut consumption may be a promising intervention for reducing negative outcomes associated with Helicobacter pylori (H. pylori) infection, a widespread bacterial infection that affects more than half of the world's population.

9 Feb 2021

Scientists grow small intestinal cells from human-induced pluripotent stem cells

A team of scientists from Japan have found success in growing small intestinal cells, akin to those found in the human body, from human-induced pluripotent stem cells.

8 Feb 2021

POSTECH researchers discover mechanism behind intestinal epithelial lymphocyte differentiation

The intestine harbors the largest number of immune cells in our body. Since the intestine is constantly exposed to various antigens like bacteria and food, appropriate induction of gut immune cells plays a pivotal role in gut homeostasis.

4 Feb 2021

Insulin nanoparticles may become an alternative to insulin injections for diabetic patients

Scientists at Nanyang Technological University, Singapore (NTU Singapore) have developed insulin nanoparticles that may one day become the basis for an oral medicine, and an alternative to insulin injections for diabetic patients.

12 Jan 2021

FDA approves first generic glucagon for injection to treat severe hypoglycemia

Today, the U.S. Food and Drug Administration approved the first generic of glucagon for injection USP, 1 mg/vial packaged in an emergency kit, for the treatment of severe hypoglycemia (very low blood sugar), which may occur in patients with diabetes mellitus.

28 Dec 2020